BioLargo, Inc. (OTCQX: BLGO) filed a Current Report on Form 8-K on November 2, 2026, disclosing updates regarding the commercial progress of its subsidiary, Clyra Medical Technologies, Inc.
The filing references a fireside chat video released by the company, featuring Dennis P. Calvert, President and CEO of BioLargo and Chairman of Clyra, and Steve Harrison, CEO of Clyra. The discussion focused on the performance of ViaCLYR, an FDA 510(k)-cleared wound irrigation solution, following its commercial launch in March 2026.
According to the filing, the product has been utilized in the treatment of hundreds of patients since its launch, receiving favorable feedback from clinicians regarding its performance and clinical utility. BioLargo reported that Clyra is currently progressing through clinical evaluations and approval processes with several U.S. healthcare systems. The company is farthest along with a system operating nearly 20 hospitals and 200 clinics, where ViaCLYR is used for advanced wound and burn care.
The filing also details Clyra's distribution infrastructure. Advanced Solution provides access to approximately 85% of the U.S. market, while Spartan Medical serves federal healthcare customers, including the Department of Defense and Veterans Affairs. Additionally, Al Hikma provides distribution coverage across 18 countries in the Middle East, where product registrations are underway.
Clyra is reportedly preparing to introduce an additional product line in collaboration with a confidential strategic partner. BioLargo noted that the company is competing at the highest level of the industry, with clinicians embracing the products and health systems moving toward adoption.
